Understanding the pathogenetic mechanisms of SIRS and sepsis and development of innovative therapies of sepsis

Naoki Aikawa, Seitaro Fujishima

Research output: Contribution to journalArticle

Abstract

The concept of systemic inflammatory response syndrome (SIRS) was introduced in 1992 to define and objectively diagnose sepsis. Over the last decade, the definition of sepsis has been used for inclusion criteria of multicenter trials to develop innovative therapies of sepsis. With the recent understanding of the pathogenetic mechanisms of sepsis, many drugs have been tested, but only two drugs (activated protein C and neutrophil-elastase inhibitor) have been approved for clinical use in sepsis or SIRS. Further understanding of basic pathophysiology of SIRS and sepsis holds promise to develop a new therapeutic strategy to improve survival of patients with SIRS and sepsis.

Original languageEnglish
Pages (from-to)2173-2176
Number of pages4
JournalNippon rinsho. Japanese journal of clinical medicine
Volume62
Issue number12
Publication statusPublished - 2004

Fingerprint

Systemic Inflammatory Response Syndrome
Investigational Therapies
Sepsis
Secretory Proteinase Inhibitory Proteins
Protein C
Pharmaceutical Preparations
Multicenter Studies
Survival

Cite this

@article{d2df230b31db422fa99096fa7335216f,
title = "Understanding the pathogenetic mechanisms of SIRS and sepsis and development of innovative therapies of sepsis",
abstract = "The concept of systemic inflammatory response syndrome (SIRS) was introduced in 1992 to define and objectively diagnose sepsis. Over the last decade, the definition of sepsis has been used for inclusion criteria of multicenter trials to develop innovative therapies of sepsis. With the recent understanding of the pathogenetic mechanisms of sepsis, many drugs have been tested, but only two drugs (activated protein C and neutrophil-elastase inhibitor) have been approved for clinical use in sepsis or SIRS. Further understanding of basic pathophysiology of SIRS and sepsis holds promise to develop a new therapeutic strategy to improve survival of patients with SIRS and sepsis.",
author = "Naoki Aikawa and Seitaro Fujishima",
year = "2004",
language = "English",
volume = "62",
pages = "2173--2176",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "12",

}

TY - JOUR

T1 - Understanding the pathogenetic mechanisms of SIRS and sepsis and development of innovative therapies of sepsis

AU - Aikawa, Naoki

AU - Fujishima, Seitaro

PY - 2004

Y1 - 2004

N2 - The concept of systemic inflammatory response syndrome (SIRS) was introduced in 1992 to define and objectively diagnose sepsis. Over the last decade, the definition of sepsis has been used for inclusion criteria of multicenter trials to develop innovative therapies of sepsis. With the recent understanding of the pathogenetic mechanisms of sepsis, many drugs have been tested, but only two drugs (activated protein C and neutrophil-elastase inhibitor) have been approved for clinical use in sepsis or SIRS. Further understanding of basic pathophysiology of SIRS and sepsis holds promise to develop a new therapeutic strategy to improve survival of patients with SIRS and sepsis.

AB - The concept of systemic inflammatory response syndrome (SIRS) was introduced in 1992 to define and objectively diagnose sepsis. Over the last decade, the definition of sepsis has been used for inclusion criteria of multicenter trials to develop innovative therapies of sepsis. With the recent understanding of the pathogenetic mechanisms of sepsis, many drugs have been tested, but only two drugs (activated protein C and neutrophil-elastase inhibitor) have been approved for clinical use in sepsis or SIRS. Further understanding of basic pathophysiology of SIRS and sepsis holds promise to develop a new therapeutic strategy to improve survival of patients with SIRS and sepsis.

UR - http://www.scopus.com/inward/record.url?scp=16644387821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644387821&partnerID=8YFLogxK

M3 - Article

C2 - 15597781

AN - SCOPUS:16644387821

VL - 62

SP - 2173

EP - 2176

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 12

ER -